IOVA
Iovance Biotherapeutics, Inc. · Healthcare
3.30
3.79%(-0.13)
Prev. Close3.32
0.61%(+0.02)
Pre-marketLast Updated: — ET
52W L: $1.6452W H: $5.63
$3.31
CHG-1.68 (-33.72%)
H$5.63
L$3.25
VOL246M
IOVA (1h)
Iovance Biotherapeutics, Inc. · Healthcare
Iovance Biotherapeutics is positioned for multi-year growth, with Amtagvi sales and pipeline momentum accelerating despite recent share price volatility. Real-world Amtagvi data shows a 44% ORR and 73% disease control, outperforming pivotal trial results and driving increased physician adoption in less heavily pretreated patients. IOVA's pipeline catalysts include pivotal NSCLC data in 2024, sarcoma expansion with efficient trial design, and global regulatory reviews, supporting a blockbuster potential beyond melanoma.
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) have been assigned an average recommendation of "Hold" from the twelve brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and six have issued a buy
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,400 shares of Iovance's common stock to one new, non-executive employee.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines aiming to address a specific type of cancer with particular dedicated mechanisms.
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Roche Corleen M.
officer: Chief Financial Officer
132,200 SH @ $0.00
2026-03-09
Vogt Frederick G
director, officer: Interim CEO & General Counsel
235,000 SH @ $0.00
2026-03-09
Puri Raj K.
officer: Chief Regulatory Officer
117,500 SH @ $0.00
2026-03-09
GRAF FINCKENSTEIN FRIEDRICH
officer: Chief Medical Officer
58,750 SH @ $0.00
2026-03-09
Kirby Daniel Gordon
officer: Chief Commercial Officer
132,200 SH @ $0.00
2026-03-09
BILINSKY IGOR
officer: Chief Operating Officer
117,500 SH @ $0.00
2026-03-09
Vogt Frederick G
director, officer: Interim CEO & General Counsel
62,493 SH @ $0.00
2026-03-05
Vogt Frederick G
director, officer: Interim CEO & General Counsel
26,755 SH @ $4.58
2026-03-05